RBC Capital Keeps Their Buy Rating on Evolent Health (EVH)
Evolent Health (EVH): A Buy Rating With Robust Growth and Strategic Initiatives
Evolent Health Price Target Cut to $31.00/Share From $34.00 by JMP Securities
Evolent Health Analyst Ratings
Evolvent Health's Strong Q2 Performance and Promising Outlook Bolster Buy Rating
J.P. Morgan Maintains Evolent Health(EVH.US) With Buy Rating
Evolent Health Analyst Ratings
Truist Financial Maintains Evolent Health(EVH.US) With Hold Rating
Truist Financial Reaffirms Their Hold Rating on Evolent Health (EVH)
RBC Capital Maintains Evolent Health(EVH.US) With Buy Rating, Maintains Target Price $42
RBC Capital Keeps Their Buy Rating on Evolent Health (EVH)
TD Cowen Sticks to Its Buy Rating for Evolent Health (EVH)
Evolent Health (EVH) Receives a Hold From Truist Financial
Analysts Have Conflicting Sentiments on These Healthcare Companies: Praxis Precision Medicines (PRAX), Iovance Biotherapeutics (IOVA) and Evolent Health (EVH)
Truist Adjusts Evolent Health's Price Target to $28 From $34, Notes Near-Term Lack of Claims Visibility; Keeps Hold Rating
Evolent Health Analyst Ratings
Evolent Health (EVH) Receives a Buy From RBC Capital
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sangamo Biosciences (SGMO), Xencor (XNCR) and Evolent Health (EVH)
Analysts Offer Insights on Healthcare Companies: Altimmune (ALT), Evolent Health (EVH) and Cormedix (CRMD)
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Evolent Health (EVH) and BioMarin Pharmaceutical (BMRN)